Catalent Inc (NYSE:CTLT) was the target of unusually large options trading on Tuesday. Traders bought 2,407 call options on the company. This represents an increase of 1,359% compared to the typical volume of 165 call options.
CTLT has been the subject of a number of research reports. Royal Bank of Canada set a $45.00 price target on Catalent and gave the stock a “buy” rating in a research note on Friday, November 16th. Zacks Investment Research upgraded Catalent from a “sell” rating to a “hold” rating in a research note on Tuesday, October 30th. First Analysis upgraded Catalent from a “neutral” rating to an “outperform” rating and decreased their target price for the company from $47.00 to $43.00 in a research note on Wednesday, November 7th. ValuEngine upgraded Catalent from a “hold” rating to a “buy” rating in a research note on Monday, November 12th. Finally, TheStreet downgraded Catalent from a “b-” rating to a “c+” rating in a research note on Wednesday, November 7th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Catalent has a consensus rating of “Buy” and a consensus price target of $47.78.
In other news, Director John J. Greisch purchased 13,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 8th. The stock was acquired at an average cost of $37.61 per share, for a total transaction of $488,930.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.40% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. First Bank & Trust raised its holdings in Catalent by 13.9% during the fourth quarter. First Bank & Trust now owns 4,600 shares of the company’s stock worth $143,000 after purchasing an additional 563 shares in the last quarter. Strs Ohio raised its holdings in Catalent by 9.9% during the fourth quarter. Strs Ohio now owns 6,598 shares of the company’s stock worth $205,000 after purchasing an additional 593 shares in the last quarter. Diversified Trust Co raised its holdings in Catalent by 9.1% during the third quarter. Diversified Trust Co now owns 11,900 shares of the company’s stock worth $542,000 after purchasing an additional 995 shares in the last quarter. Atria Investments LLC raised its holdings in Catalent by 12.6% during the third quarter. Atria Investments LLC now owns 10,208 shares of the company’s stock worth $465,000 after purchasing an additional 1,144 shares in the last quarter. Finally, Retirement Systems of Alabama raised its holdings in Catalent by 0.7% during the fourth quarter. Retirement Systems of Alabama now owns 188,448 shares of the company’s stock worth $5,876,000 after purchasing an additional 1,256 shares in the last quarter. 96.76% of the stock is currently owned by hedge funds and other institutional investors.
CTLT opened at $39.23 on Wednesday. The company has a market cap of $5.43 billion, a PE ratio of 24.67, a price-to-earnings-growth ratio of 2.20 and a beta of 1.66. The company has a current ratio of 2.05, a quick ratio of 1.61 and a debt-to-equity ratio of 1.44. Catalent has a twelve month low of $29.23 and a twelve month high of $46.43.
Catalent (NYSE:CTLT) last released its quarterly earnings results on Tuesday, February 5th. The company reported $0.45 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.08. The company had revenue of $623.00 million for the quarter, compared to analysts’ expectations of $608.38 million. Catalent had a return on equity of 19.13% and a net margin of 2.65%. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.45 earnings per share. As a group, analysts anticipate that Catalent will post 1.65 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This article was first posted by Enterprise Leader and is the property of of Enterprise Leader. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://theenterpriseleader.com/2019/02/06/stock-traders-purchase-large-volume-of-call-options-on-catalent-ctlt.html.
Catalent Company Profile
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.